Rhodococcus equi foal pneumonia: Update on epidemiology, immunity, treatment and prevention.
Authors: Bordin Angela I, Huber Laura, Sanz Macarena G, Cohen Noah D
Journal: Equine veterinary journal
Summary
Rhodococcus equi pneumonia remains a significant cause of morbidity and mortality in foals worldwide, prompting Bordin and colleagues to synthesise recent evidence on epidemiology, immunity, treatment and prevention in this 2022 narrative review. Screening programmes designed to identify and treat subclinical infections earlier have improved outcomes in some settings but have inadvertently driven antimicrobial resistance in North American populations—a critical concern requiring careful reassessment of screening protocols. Whilst protective immunity mechanisms remain incompletely understood, emerging data suggest innate immune responses play a dual role in direct bacterial killing and in priming adaptive immunity, offering potential targets for future intervention. Current treatment relies on macrolide-rifampin combinations, yet significant knowledge gaps persist regarding optimal antimicrobial synergy and resistance containment strategies. Passive immunisation via hyperimmune plasma remains the only proven commercial prevention method currently available, though its cost, labour intensity and foal-related risks highlight an urgent need for vaccine development and alternative immunisation approaches to make R. equi prevention more accessible and practical for practitioners managing at-risk foal populations.
Read the full abstract on PubMed
Practical Takeaways
- •While early screening and treatment reduce mortality in foals, practitioners must balance benefits against contribution to antimicrobial resistance; judicious use of screening protocols is warranted
- •Macrolide plus rifampin remains your first-line treatment for confirmed R. equi pneumonia, but ongoing research may identify superior combinations—stay updated with new evidence
- •Passive immunisation (hyperimmune serum) is your best current prevention tool for high-risk foals, though cost and logistics require careful management planning and client communication about realistic effectiveness
Key Findings
- •Screening tests for early detection of subclinical R. equi pneumonia have reduced mortality but are linked to emergence of antimicrobial-resistant strains in North America
- •Innate immune responses are critical for both direct killing of R. equi and orchestrating adaptive immune responses, though specific correlates of protective immunity remain unclear
- •Macrolide antimicrobials combined with rifampin remain the recommended treatment despite ongoing need to identify optimal antimicrobial combinations
- •Passive immunisation is currently the only commercially available method to effectively reduce R. equi pneumonia incidence, but alternatives are urgently needed due to cost, labour intensity, and associated risks